In PIK3CA-mutated HNSCC, these allosteric inhibitors provide sustained suppression of oncogenic signaling pathways while minimizing interference with normal PI3Kβ/δ/γ functions in healthy tissues, thereby improving the therapeutic window. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.